Unrealized potential of drug repositioning in europe during COVID-19 and beyond: a physcian’s perspective

Autor: Ahmed B. Bayoumy, F. Crouwel, Cjj Mulder, Azhar Ansari, N. K. H. de Boer

Publikováno v: Journal of Pharmaceutical Policy and Practice, Vol 13, Iss 1, Pp 1-9 (2020)
Bayoumy, A B, De Boer, N K H, Ansari, A R, Crouwel, F & Mulder, C J J 2020, ' Unrealized potential of drug repositioning in europe during COVID-19 and beyond : A physcian's perspective ', Journal of pharmaceutical policy and practice, vol. 13, no. 1, 45 . https://doi.org/10.1186/s40545-020-00249-9
Journal of Pharmaceutical Policy and Practice

Drug repositioning is the scientific strategy of investigating existing drugs for additional clinical indications. The advantages of drug repositioning are that it benefits patients and that it adds new indications to existing drugs for lower costs c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a55e8ac44a53cf304bfe48c588808b3
http://link.springer.com/article/10.1186/s40545-020-00249-9

Multitarget Stool DNA Test Performance in an Average-Risk Colorectal Cancer Screening Population

Autor: Linda J.W. Bosch, Kathleen L.J. Daenen, Gerrit A. Meijer, Barry M. Berger, Michael J. Domanico, S.T. van Turenhout, Veerle M.H. Coupé, Sandra Mongera, Cjj Mulder, Graham P. Lidgard, E. Dekker, Esther M. Stoop, T. R. de Wijkerslooth, M. van Engeland, Beatriz Carvalho, Ernst J. Kuipers, Christian Rausch, Veerle Melotte

Publikováno v: American Journal of Gastroenterology, 114(12), 1909-1918. Springer Nature
The American Journal of Gastroenterology
American journal of gastroenterology, 114(12), 1909-1918. Springer Nature
American Journal of Gastroenterology, 114(12), 1909-1918. Nature Publishing Group
Bosch, L J W, Melotte, V, Mongera, S, Daenen, K L J, Coupé, V M H, van Turenhout, S T, Stoop, E M, de Wijkerslooth, T R, Mulder, C J J, Rausch, C, Kuipers, E J, Dekker, E, Domanico, M J, Lidgard, G P, Berger, B M, van Engeland, M, Carvalho, B & Meijer, G A 2019, ' Multitarget Stool DNA Test Performance in an Average-Risk Colorectal Cancer Screening Population ', American Journal of Gastroenterology, vol. 114, no. 12, pp. 1909-1918 . https://doi.org/10.14309/ajg.0000000000000445

INTRODUCTION: We set out to evaluate the performance of a multitarget stool DNA (MT-sDNA) in an average-risk colonoscopy-controlled colorectal cancer (CRC) screening population. MT-sDNA stool test results were evaluated against fecal immunochemical t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a472cbe7d8462b2f42d2cc76d355c0d
https://pure.eur.nl/en/publications/81681327-d192-4f50-93cd-9c08e3a3c924

A Pitfall in Suspected (refractory) Celiac Disease: Losartan-Induced Enteropathy

Autor: Gerd Bouma, Cjj Mulder, R J Robijn, E. A. Neefjes-Borst, T van Gils

Publikováno v: American Journal of Gastroenterology, 112(11), 1754-1755. Springer Nature
Van Gils, T, Robijn, R J, Bouma, G, Neefjes-Borst, E A & Mulder, C J J 2017, ' A Pitfall in Suspected (refractory) Celiac Disease : Losartan-Induced Enteropathy ', American Journal of Gastroenterology, vol. 112, no. 11, pp. 1754-1755 . https://doi.org/10.1038/ajg.2017.281

To the Editor: The main cause of villous atrophy in western countries is celiac disease (CD). In case of negative CD antibodies, other causes of villous atrophy, such as collagenous sprue and drug-induced enteropathy have to be excluded before a pati

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b80f19ffc6fc9ee743414cc122751ba8
https://research.vumc.nl/en/publications/e3738ca3-62a2-420b-a7bf-6e2355528463

Lymphoma development and survival in refractory coeliac disease type II:Histological response as prognostic factor

Autor: Cjj Mulder, Otto Visser, Birgit I. Witte, Nicolette J. Wierdsma, Hetty J. Bontkes, T van Gils, Gerd Bouma, G.J. Tack, Rlj van Wanrooij, Petula Nijeboer

Publikováno v: Nijeboer, P, van Wanrooij, R L J, van Gils, T, Wierdsma, N J, Tack, G J, Witte, B I, Bontkes, H J, Visser, O, Mulder, C J J & Bouma, G 2017, ' Lymphoma development and survival in refractory coeliac disease type II : Histological response as prognostic factor ', United European Gastroenterology Journal, vol. 5, no. 2, pp. 208-217 . https://doi.org/10.1177/2050640616646529
United European Gastroenterology Journal, 5(2), 208-217. SAGE Publications Inc.

Background: Refractory coeliac disease type II (RCDII) frequently transforms into an enteropathy-associated T-cell lymphoma (EATL) and therefore requires intensive treatment. Current evaluated treatment strategies for RCDII include cladribine (2-CdA)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ee7dea832b8aef00d8b195ae9a20aef
https://research.vumc.nl/en/publications/e7d5e080-1130-4863-a1a5-a9b07c2c085d

Allopurinol safely and effectively optimises thiopurine metabolites in patients with autoimmune hepatitis

Autor: Y. S. de Boer, Gerd Bouma, C.M.J. van Nieuwkerk, N. M. F. van Gerven, N. K. H. de Boer, Cjj Mulder

Publikováno v: Alimentary Pharmacology and Therapeutics, 37(6), 640-646
de Boer, Y S, van Gerven, N M F, de Boer, K H N, Mulder, C J J, Bouma, G & van Nieuwkerk, C M J 2013, ' Allopurinol safely and effectively optimises thiopurine metabolites in patients with autoimmune hepatitis ', Alimentary Pharmacology and Therapeutics, vol. 37, no. 6, pp. 640-646 . https://doi.org/10.1111/apt.12223

Summary Background Ten percent of patients with autoimmune hepatitis (AIH) are nonresponsive or intolerant to thiopurine therapy. A skewed metabolism, leading to the preferential generation of (hepato)toxic thiopurine metabolites (6-MMPs) instead of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35a2e3d80271a435cbd920cb5d7a7d57
https://doi.org/10.1111/apt.12223